Sign In
Buy ENTA
$13.37
+0.710 (+5.61%)
At Close: Jun 22, 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced
Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial
08:06am, Tuesday, 20'th Jun 2023
Shares of Enanta Pharmaceuticals Inc. ENTA, -0.25% gained 5% premarket on Tuesday after the biotech company released positive results from an early-phase clinical trial of a treatment for respiratory
Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference
07:00am, Wednesday, 31'st May 2023
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced t
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
07:03pm, Monday, 08'th May 2023
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.79 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $1.63 per share a year ago.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
07:00am, Tuesday, 07'th Mar 2023
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced t
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
10:15pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 8.55% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2023 Earnings Call Transcript
10:12pm, Tuesday, 07'th Feb 2023
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q1 2023 Earnings Conference Call February 7, 2023 4:30 PM ET Company Participants Jennifer Viera – Investor Relations Jay Luly – President and Chief Exe
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
06:49pm, Tuesday, 07'th Feb 2023
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 8.55% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
11:20am, Friday, 09'th Dec 2022 Zacks Investment Research
Smart Beta ETF report for PJP
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates
10:15pm, Monday, 21'st Nov 2022 Zacks Investment Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 7.30% and 9.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates
06:48pm, Monday, 21'st Nov 2022
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 7.30% and 9.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
11:20am, Tuesday, 15'th Nov 2022 Zacks Investment Research
Sector ETF report for PJP
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Misses Revenue Estimates
02:15pm, Monday, 14'th Nov 2022 Zacks Investment Research
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of 0% and 54.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for t
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates
10:35pm, Thursday, 10'th Nov 2022 Zacks Investment Research
MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th
